View Clinical Trial (Medical Research Study)
Controlled Study of the Ability of a Smokefree Tobacco Product to Increase the Quit Rate Among Cigarette Smokers - NCT00843622-97239(Clinical Trial 271716)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Portland |
|
State:
|
|
OR |
| Zip Code: |
|
97239 |
| Conditions: |
|
Cigarette Smoking |
| Purpose: |
|
The study aims to assess if use of a low-nitrosamine, Swedish, smokefree tobacco product for
oral use ("snus") can increase the quit rate among cigarette smokers who wish to stop
smoking
|
| Study summary: |
|
In a multicenter, double-blind, placebo-controlled setting, participants are randomly
allocated to either a smokefree, oral tobacco product or a non-tobacco, non-nicotine placebo
product with identical flavoring and physical appearance. The study consists of three
phases: Study Product Test Period (4 weeks), Intervention Phase (12 weeks), and a Follow-Up
Phase (12 weeks). The participants are all cigarette smokers who are motivated to quit. They
are encouraged to gradually substitute as many cigarettes as possible with study products
during the Study Product Test Period and to refrain from all cigarettes at the latest by the
first day of Week 5. Use of study products will continue during the 12 week Intervention
Phase. The participants are encouraged to cut down on use of study products during the last
3 weeks to avoid a too abrupt ending of nicotine intake.
All subjects are encouraged to continue in the study for clinical follow-up independent of
smoking status although use of study products is discontinued during the Follow-Up Phase. If
a subject has managed to quit smoking during the Intervention Phase but there is an imminent
danger of smoking relapse during the Follow-Up Phase, that subject is informed that use of
nicotine replacement therapy or a smokefree tobacco product is a better option in terms of
health risks than a smoking relapse. |
| Criteria: |
|
Inclusion Criteria:
- Cigarette smoker who smoke more than 9 cigarettes per day (average during past month)
- Daily smoking more than 1 year
- Motivated to quit smoking using a smokefree tobacco product
- Good general health
Exclusion Criteria:
- Use of smokefree/smokeless tobacco during past 6 months or any type of pharmaceutical
product for smoking cessation during past 3 months
- Unable to refrain from nicotine replacement therapy during the study
- Current oral condition that could be made worse by study interventions
- History of clinically significant renal, hepatic, neurological, or chronic pulmonary
disease that in the judgement of the investigator might preclude participation
- History of significant cardiovascular disease, including myocardial infarction,
within the last 3 months, significant cardiac arrythmias, or poorly controlled
hypertension that in the judgement of the investigator might preclude participation
- History of alcohol or substance abuse other than cigarette smoking within the past
year |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
February 2, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|